Gut Brain Axis

Description

The gut-brain axis is the bidirectional communication network between the gastrointestinal tract and the central nervous system, mediated through neural (vagus nerve), immune (cytokines, immune cell trafficking), endocrine (cortisol, gut hormones), and metabolic (microbial metabolites) channels. The gut microbiome -- comprising trillions of bacteria, fungi, and viruses -- produces neuroactive metabolites including short-chain fatty acids (particularly butyrate), neurotransmitter precursors, and pro-inflammatory molecules that can influence brain function and neuroinflammatory status.

In Alzheimer's disease, the gut-brain axis has emerged as a significant modifiable risk pathway through several mechanisms. The critical connection involves butyrate, a short-chain fatty acid produced by beneficial gut bacteria, which upregulates expression of the antimicrobial peptide LL-37 (cathelicidin) via the CAMP gene. LL-37 serves as a chaperone that prevents Abeta fibrillation at 1:1 molar ratios, meaning that gut dysbiosis leading to reduced butyrate production can compromise a key anti-amyloid immune checkpoint. The oral microbiome represents another entry point: the periodontal pathogen P. gingivalis disseminates from the oral cavity to the brain via transient bacteremia, where its gingipain proteases directly sabotage the autophagy-lysosomal system by inhibiting v-ATPase, cleaving VAMP8 (blocking autophagosome-lysosome fusion), and suppressing TFEB-mediated lysosomal biogenesis.

Vitamin D signaling intersects with the gut-brain axis: the CAMP gene (encoding LL-37) contains a Vitamin D Response Element (VDRE), linking vitamin D deficiency -- a well-established AD risk factor -- to reduced antimicrobial peptide defense. P. gingivalis gingipains also degrade LL-37 directly, breaking the immune checkpoint from both sides. This creates a model where oral hygiene, gut microbiome composition, and vitamin D status collectively modulate a host defense pathway that protects against amyloid aggregation.

Convergence Nodes

• Neuroimmune Interface -- Gut-derived immune signals modulate microglial activation state and neuroinflammatory tone
• Compensatory Paradigm Nexus -- Abeta as antimicrobial peptide represents a defense against gut-derived and oral pathogens

Prize Entrants

• Annalise Barron -- Identified butyrate-LL-37-Abeta chaperone axis linking gut microbiome to anti-amyloid defense; demonstrated P. gingivalis gingipain degradation of LL-37; connected vitamin D/VDRE signaling to antimicrobial peptide expression
• Stephen Dominy -- Demonstrated P. gingivalis systemic dissemination from oral cavity to brain; identified specific gingipain-mediated sabotage of v-ATPase, VAMP8, and TFEB in the neuronal autophagy system
• Jeevan Pradhan -- Integrated P. gingivalis infection and ceramide ratio dysregulation into systems-level AD model

External Scientists

• Rudolph Tanzi -- Abeta antimicrobial function providing context for pathogen-driven amyloid responses
• Sangram Sisodia -- Gut microbiome modulation of amyloid pathology in mouse models

Key Open Questions

• Can probiotic or dietary interventions that increase butyrate-producing gut bacteria restore LL-37 levels and reduce AD risk?
• Is periodontal disease (P. gingivalis infection) a causal contributor to AD, or a correlate of shared risk factors?
• How does the gut-brain axis interact with APOE genotype -- does APOE4 alter gut microbiome composition or gut barrier integrity?
• Can the LL-37 chaperone checkpoint be pharmacologically augmented as a therapeutic strategy against amyloid aggregation?
• Does the oral microbiome contribute more significantly than the gut microbiome to AD risk, or are both important through different mechanisms?